Ignite Creation Date:
2024-05-06 @ 1:46 PM
Last Modification Date:
2024-10-26 @ 1:19 PM
Study NCT ID:
NCT04111705
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-07
First Post:
2019-08-30
Brief Title:
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer
Sponsor:
Organization:
Intergroupe Francophone de Cancerologie Thoracique